论文部分内容阅读
我们建议投资者从更长远的角度看这次产业政策的投资机会,关注研发类的生物医药类上市公司,如天坛生物、双鹭药业、达安基因以及长春高新等。
Investors are advised to look at the investment opportunities in this industrial policy in the longer term and focus on biomedical listed companies in research and development such as Tiantan Biologicals, Shuanglu Pharmaceutical, Daan Gene and Changchun High-tech.